Doxorubicin-Polysorbate 80 conjugates: targeting effective and sustained delivery to the brain

Simple item page
dc.contributor.authorRam Prasad, S
dc.contributor.authorLeena, SS
dc.contributor.authorDeepthi, A
dc.contributor.authorResmi, AN
dc.contributor.authorJayasree, RS
dc.contributor.authorSandhya, KS
dc.contributor.authorJayakrishnan, A
dc.date.accessioned2024-08-06T06:15:07Z
dc.date.available2024-08-06T06:15:07Z
dc.date.issued2024-05
dc.description.abstractTargeting therapeutic agents to the brain to treat the central nervous system (CNS) diseases is a major challenge due to the blood-brain-barrier (BBB). In this study, an attempt was made to deliver a model drug such as doxorubicin (DOX) to the brain in a mice model through DOX-Polysorbate 80 (DOX-PS80) conjugates. DOX was successfully conjugated with the non-ionic surfactant Polysorbate 80 (PS80) by carbamate linkage and the conjugate was characterized by different spectroscopic techniques such as FTIR, UV-Visible and NMR. The DOX conjugation efficacy was found to be 43.69 ± 4.72 %. The in vitro cumulative release of DOX from the conjugates was found to be 4.9 ± 0.8 % in PBS of pH 7.3 and 3.9 ± 0.6 % in simulated cerebrospinal fluid (CSF) of pH 7.3 at the end of 10 days. In vitro BBB permeability assay was carried out using bEnd.3 cells and DOX-PS80 conjugate showed a 3-fold increase in BBB permeability compared to controls. In vitro cytotoxicity assay using U251 human glioblastoma cells showed an IC50 value of 38.10 µg/mL for DOX-PS80. Cell uptake studies revealed that DOX-PS80 was effectively taken up (90%) by the bEnd.3 and U251 cells and localized in cytoplasm at the end of 24 h. Tumor spheroid assay and in vivo experiments in Swiss albino mice demonstrated the possibility of DOX-PS80 conjugate crossing the BBB and delivering the drug molecules to the target site for treating CNS disorders.
dc.identifier.citationRam Prasad S, Leena SS, Deepthi A, Resmi AN, Jayasree RS, Sandhya KS and Jayakrishnan A. Doxorubicin-Polysorbate 80 conjugates: targeting effective and sustained delivery to the brain. RSC pharmaceutics 2024.Doi:10.1039/D4PM00053F
dc.identifier.urihttps://dx.doi.org/10.26434/chemrxiv-2024-gspzt
dc.identifier.urihttps://dspace.sctimst.ac.in/handle/123456789/11548
dc.publisherRSC pharmaceutics
dc.titleDoxorubicin-Polysorbate 80 conjugates: targeting effective and sustained delivery to the brain
dc.typeArticle
Files
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Journal Articles